Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Company Update
April 2009
Safe HarbourSafe Harbour
This presentation includes forward-looking statements.This presentation includes forward looking statements.Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the p , g y , g gavailability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report.
MorphoSys at a Glancep y
An independent antibody company
Company Broad, attractive pipeline with partnered & un-partnered programs in various indicationsTherapeutic & research antibody segmentsTherapeutic & research antibody segments
OrganizationHQ Martinsried (Munich)/D, subsidiaries in Düsseldorf/D Oxford/UK & Raleigh/USAOrganization Düsseldorf/D, Oxford/UK & Raleigh/USA343 employees worldwide
Frankfurt Stock Exchange TecDAXListed
Frankfurt Stock Exchange, TecDAXADR Level 1
L di i t H CAL l tfTechnology
Leading, proprietary HuCAL platformStrong & undisputed patent estate
Financials Profitable strong balance sheet
© MorphoSys AG© MorphoSys AG
Financials Profitable, strong balance sheet
MorphoSys AG – Company Update – April 2009 Page 3
Financial Strength in the Downturng
Strong balance sheet with > € 130 million in cash
Operational cash flow in 2008 of approximately € 29 million
Secure revenues 2009 – 2017 in amount of > € 400 million
Milestone & royalty potential >> € 1 billion
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 4
HuCAL PLATINUM: Technology Leadershipgy p
HuCAL stands for Human Combinatorial Antibody Library
Modular gene design & construction
Antibodies are fully humanModular gene construction enables systematic optimization of antibody lead candidates f h th ti li tifor each therapeutic applicationProprietary phage-based CysDisplay screening systemProprietary AutoCAL system for high throughput
© MorphoSys AG© MorphoSys AG
HuCAL PLATINUM launched in December 2008
MorphoSys AG – Company Update – April 2009 Page 5
HuCAL PLATINUMBrighter than GOLD
GOLD PLATINUMLibrary size 12 Mrd. 45 Mrd.
Underlying database 1997 2008
Di it f i l t d tib di 1 25Diversity of isolated antibodies 1x 25x
Affinities 1x 4x
Production 1x 3x
HUCAL - Commercial Success Story
Production 1x 3x
More than 50 active therapeutic programsMore than 1,000 custom research antibody projects concludedHuCAL GOLD has generated more than € 200 million in revenues in the form of license and success-based payments and research servicesRoyalties on HuCAL GOLD-based products still to come
© MorphoSys AG© MorphoSys AG Seite 6MorphoSys AG – Company Update – April 2009
Robust Intellectual Property Protected by p y yCore Patent Families
HuCAL Library Design and Use (~2016 expiry)5 US Patents2 EP Patents (several EU states)2 AU PatentsPending applications: CA EP JP USPending applications: CA EP JP US
TRInucleotide Mutagenesis (JHU excl. license) (~2013 expiry)1 US Patent; 1 EP and 1 JP patent; pending in CA
Di lfid Di l (C Di l ) ( 2020 i )Disulfide Display (CysDisplay) (~2020 expiry)1 US and 1 EP PatentPending applications: AU CA EP IL JP NO US
Technology Development (HuCAL PLATINUM®)Several applications pendingCo-exclusive access to various Dyax biologics patent families
Patent applications for antibody drug candidatesPatent filings and inlicensed patents for proprietary candidates
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 7
Business Segmentsg
Therapeutic Antibodies Research Antibodies
Broad partnered pipeline, underpinned by Novartis,
ensures substantial cash-flow
Built by merging:
Partnering with leadingh i
Top 20 research antibodypharma companies company
Proprietary pipeline bringseven greater upside
Platform to increase uptake ofHuCAL technology
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 8
Value Through Strong Partnershipsg g p
NovartisAstellas
2007 2008 2009 2010 2011 2012
PfizerShionogiSchering-PloughDaiichi SankyoMerck & Co.Boehringer IngelheimOncomedEli LillyRoche
Committed termOptionalExtensions 2008
B S h iBayer ScheringCentocorProchon
Ongoing antibody programs
58 active partnered therapeutic antibody programsE t d d t hi i 2008 id ti f th 15 dditi l
© MorphoSys AG© MorphoSys AG
Extended partnerships in 2008 provide options for more than 15 additional programs
MorphoSys AG – Company Update – April 2009 Page 9
Current Product Pipeline:p62 Programs Ongoing
Name Partner Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
Gantenerumab(R1450) Roche Alzheimer‘s
Disease
BHQ880 Novartis Cancer
n.d. Centocor Immunology/Cancer
31 Partnered Programs Various Various*
58 Partnered Programs
Programs23 Partnered Programs Various Various*
MOR103 - Rheumatoid MOR103 - Arthritis
MOR202 - Cancer 3 Proprietary Programs
MOR203 - Cancer
n.d. MorphoSys/ Novartis n.d. 1 Pre-Dev. Program
© MorphoSys AG© MorphoSys AG Page 10MorphoSys AG – Company Update – April 2009
* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases
Partnered Therapeutic Programs: Structurep g
Partner provides target molecule, assay, disease expertisePartner receives exclusive target license first come-firstPartner receives exclusive target license, first come first servedTarget is reserved and cannot be pursued by other partners or independently by MorphoSysindependently by MorphoSysMorphoSys uses its technology to generate optimized drug candidates against the target
Target Universeg
Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
MorphoSys Partner
© MorphoSys AG© MorphoSys AG
Optimised Lead Antibody
MorphoSys AG – Company Update – April 2009 Page 11
Partnerships: Typical Terms per Programp yp p g
Royalties(mid single digits)€9m - €12m
Approvalmilestonemilestone
Phase 3 milestone
Phase 1 milestone
Exclusive license fee; R&D fundingExclusive license fee; R&D funding
MorphoSys costs
Di P li i Ph 1 Ph 2 Ph 3 M k t
© MorphoSys AG© MorphoSys AG
Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
Page 12MorphoSys AG – Company Update – April 2009
Partnered HuCAL Antibodies in Clinic1. Roche‘s Alzheimer Program
Gantenerumab (R1450)HuCAL IgG1 antibodyg yTargeting amyloid-βBinds to Aβ peptidesDepolymerizes aggregated Aβp y gg g βCrosses blood-brain barrier in transgenic mouse, decreasing cerebral Aβ burden
Two Phase 1 studiesSingle dose arm completedMultiple ascending dose arm no longer recruitingp g g gMild-to-moderate Alzheimer’s patientsRandomized, double-blindAntibody behaves as expectedy p
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 13
Source: Roche
Partnered HuCAL Antibodies in Clinic2. Novartis‘s Cancer Program
BHQ880HuCAL IgG1 antibodyTargeting DKK-1− Overexpression of DKK-1 by myeloma
cells may upset the normal balance b t t bl t d t l tbetween osteoblasts and osteoclasts
− DKK-1 may play a role in preventing osteolytic bone disease in multiple myeloma patientsmyeloma patients
Phase 1 study is ongoing in the USP li i l t di t th h th iPreclinical studies support the hypothesis that BHQ880 promotes bone formation and thereby inhibits tumor-induced osteolytic diseaseyA phase 1/2 combination study in combination with Zometa/Reclast in relapsed or refractory myeloma patients h t t d i F b 2009
© MorphoSys AG© MorphoSys AG
has started in February 2009
MorphoSys AG – Company Update – April 2009 Page 14
Source: Novartis
Partnered HuCAL Antibodies in Clinic3. Centocor‘s Cancer & Inflammation Program
HuCAL-derived fully human antibody in the therapeutic area of oncologygyPhase 1 trial in oncology was started in June 2007, is ongoingIn November 2008, a phase 2 study in an additional indication (immunology) was started(immunology) was startedIND filing for phase 2 study triggered a milestone payment to MorphoSys
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 15
Partnered Business:Projected HuCAL Drugs on the Market
Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
P j ti f t d ‘ t d i li
50% 70% 40% 65%
Projection of today‘s partnered pipeline:
5 631 S b bilit f 18%
2.523 Success probability of 11%
0.52 Success probability of 25%
2 0 6Success probability of 33%
5.631 Success probability of 18%
S b bili f 9%>>100 > 9
2 0.6Success probability of 33%
Projection of committed partnered programs:
Success probability of 9%100 > 9
Projected number of marketed HuCAL drugs: > 18
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 16
Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development
Pipeline: Strategyp gy
Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
gram
s
Optimized Lead Antibody
tner
ed P
rog
Part
s
€/$
yPr
ogra
ms
PoC in Humans
Prop
rieta
ry
© MorphoSys AG© MorphoSys AG
P
MorphoSys AG – Company Update – April 2009 Page 17
Proprietary Product Pipeline:p y pFour Programs Ongoing
Name Partner Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
RheumatoidMOR103 - Rheumatoid Arthritis
MOR202 - Cancer 3 Proprietary Programs
MOR203 - Cancer
n.d. MorphoSys/ Novartis n.d. 1 Pre-Dev. Program
4 proprietary programs are currently ongoing, another target was already selectedFocus on inflammation & cancer
Target Selection
Scientific Target sources: Dedicated target scouts, co-development (e.g. Galapagos) & in-licensingRigorous target selection processMedical IP Rigorous target selection process
Detailed scientific evaluation (e.g. target biology)Medical need, therapeutic potential, developability, etc.IP: FTO and patentability
Medical IP
Commercial
© MorphoSys AG© MorphoSys AG Page 18MorphoSys AG – Company Update – April 2009
Commercial: Market potential and competition
MOR103Proprietary Inflammation Program
MOR103, a fully human HuCAL antibody targeting GM-CSFGM-CSF plays a central role in inflammation and auto-immunityGM CSF plays a central role in inflammation and auto immunity
MOR103 blocks binding of GM-CSF to its receptor with pM affinity
Primary indication: Rheumatoid arthritisCommercial opportunity: Anti-TNF therapies Enbrel, Remicade, Humira are successful biologic products for treating RA, but still under 25% of RA patients are adequately treatedPromising scientific and preclinical data
Successful completion of phase 1 in healthy volunteers (favorable safety profile after 5 cohorts led to trial-extension; in total 7 cohortssafety profile after 5 cohorts led to trial extension; in total, 7 cohorts with 9 volunteers each, were treated)
Data support development of GM-CSF mAb therapy in different inflammatory diseases (rheumatoid arthritis multiple sclerosis) andinflammatory diseases (rheumatoid arthritis, multiple sclerosis) and lung diseases (COPD, asthma)
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 19
MOR103IP and Outlook 2009
Broad patent protection for MOR103 in the US, the largest RA market:
ANTIBODYPatent applications covering key features of the MOR103
U.S. 7,455,836
key features of the MOR103 program Exclusive License
US patent covering key uses of antibodies against GM-CSF
WO 2006122797
Outlook 2009:Final results from phase 1 in healthy volunteers in Q2/2009Start of phase 1b/2a study in RA patients in H2 2009Decision on second indication, based on efficacy in disease models in 2009
© MorphoSys AG© MorphoSys AG
models in 2009
MorphoSys AG – Company Update – April 2009 Page 20
MOR202Proprietary Cancer Program
MOR202, a fully human HuCAL antibody, targeting CD38,a 45 kDa ectoenzyme heavily over-expressed in 95% of MM cell-y y plines and some leukemia linesFunction: Induces cell-killing by ADCC, CDC & apoptosisPrimary indication: Multiple myeloma (MM)Primary indication: Multiple myeloma (MM)Commercial opportunity
10 % of hematological cancers / 1% of all cancers / 2% of cancer deathsNo curative therapiesMedian survival 24 – 30 months, all patients eventually relapse
Outlook 2009:Further evaluation in animal models of multiple myelomaStart of non clinical safety study to support clinical testingStart of non-clinical safety study to support clinical testingStart of preclinical efficacy studies in second indication Production and release of mAb material for animal safety testing
© MorphoSys AG© MorphoSys AG
and in preparation for phase 1/2a clinical testing in 2010
MorphoSys AG – Company Update – April 2009 Page 21
Additional Proprietary Activitiesp y
Novartis
Nomination of first pre-development programNovartis funds joint efforts until the program
h f l li i l d l treaches formal pre-clinical developmentOption for MorphoSys to enter a formal co-developmentup to 50%
Galapagos
Access Galapagos’s proven target discovery capabilities and disease know-how Access novel antibody targets iny gbone & joint disease with a high unmet medical needComplement MOR’s development efforts in inflammation and arthritis
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 22
and arthritis
Proprietary Product Pipeline:p y pProjected Status Year-End 2009
Name Partner Indication Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
Rheumatoid
MOR103 -
Rheumatoid ArthritisRespiratoryMS
MOR202 - Cancer
MOR203 - Cancer
MOR205 C
Up to 7 Proprietary Programs
MOR205 - Cancer
MORxxx - n.d.
MORxxx - n.d.MORxxx n.d.
MORxxx - n.d.
n.d. MorphoSys/ Novartis n.d. 1 Pre-Dev. ProgramNovartis g
Establish a rich proprietary pipeline based on proven HuCAL technology
© MorphoSys AG© MorphoSys AG Page 23MorphoSys AG – Company Update – April 2009
Establish a rich proprietary pipeline based on proven HuCAL technology
Clinical Pipeline p
89Number of Partnered and Proprietary Clinical Compounds at Year-End
3
567
51
345
12
43
5
012
02005 2006 2007 2008 2009E
Phase 1 Phase 2
Clinical Antibody Pipeline is Future Value Driver
© MorphoSys AG© MorphoSys AG Page 24MorphoSys AG – Company Update – April 2009
Clinical Antibody Pipeline is Future Value Driver
Business Segmentsg
Therapeutic Antibodies Research Antibodies
Broad partnered pipeline, underpinned by Novartis,
ensures substantial cash-flow
Built by merging:
Partnering with leading h i
Top 20 research antibody pharma companies company
Proprietary pipeline brings even greater upside
Platform to increase uptake of HuCAL technology
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 25
AbD SerotecBusiness and Outlook
CUSTOM SERVICE BUSINESS
20% of MarketBUSINESS
USP: mAbs in 8 weeksOutlook:
G t f t i t iGreater footprint in diagnostics markets Research
Antibody Market: a etUS$ 1bn
CATALOG BUSINESS12 000 antibodies available
OEM BUSINESSAntibodies in bulk for
12,000 antibodies availableOutlook:
Should benefit fromstimulus package
single industrial customersOutlook:
Broaden customer base
80% of Market
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 26
stimulus package
AbD SerotecHighlights & Challenges
Profitable General market slowdown for research
Highlights Challenges
First HuCAL antibody now marketed in diagnostics kit by partner Phadia
C ti ith th 20
antibodies
Research funding doesn’t grow, e.g. NIHCooperation with more than 20
diagnostics customers
Introduction of more than 5,000 new
e.g. NIH
Weak USD and GBP compared to Euro
Write-down on UK property (Poole Real ,products to catalog
Appointment of Dieter Feger from Abbott Diagnostics to head the unit
p p y (Estate)
Abbott Diagnostics to head the unit
© MorphoSys AG© MorphoSys AG Seite 27MorphoSys AG – Company Update – April 2009
FinancialsProfit & Loss Statement (Group)
In EUR millions Q1 2009 Q1 2008
Revenues 19.1 16.3
Cost of Goods Sold 1.7 1.7
R&D Expenses 8 5 5 3R&D Expenses 8.5 5.3
S,G&A Expenses 4.8 5.2
Total Operating Expenses 14 9 12 2Total Operating Expenses 14.9 12.2
Profit from Operations 4.2 4.1
Non-Operating Income 0 9 0 6Non Operating Income 0.9 0.6
Profit Before Taxes 5.1 4.7
Income Tax Benefit/(Expense) 1.6 1.4Income Tax Benefit/(Expense) 1.6 1.4
Net Profit 3.5 3.3
Earnings per Share (diluted) in EUR 0.16 0.15
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 28
Earnings per Share (diluted) in EUR 0.16 0.15
FinancialsCondensed Balance Sheets (Group)
In EUR millions 03/31/2009 12/31/2008
Assets
Cash, Cash Equivalents & MarketableSecurities 136.1 137.9
Other Current Assets 13.5 12.3
Total Non-Current Assets 51.8 53.2
Total Assets 201.3 203.3
Liabilities
Total Current Liabilities 22.7 27.4
Total Non-Current Liabilities 12.9 13.9
Total Shareholders’ Equity 165.7 162.0
T t l Li biliti 201 3 203 3
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 29
Total Liabilities 201.3 203.3
Guidance 2009
I EUR illi 2009E* 2008A 2009E* 2008A
MorphoSys Group AbD SegmentIn EUR millions 2009E* 2008A
Total Group Revenues 80 – 85 71.6
In EUR millions 2009E* 2008A
AbD ~ 20 18.2
Group Operating Profit 8 – 11 16.4 AbD Operating
Profit Marginat least level of 2008 (%) 2%
Total proprietary R&D investmentEUR 18 – 20 million Success-based payments will amount to
approximately EUR10 million
MorphoSys Group
MOR103 / MOR202
pp yProprietary R&D spend will double to EUR18 to EUR20 million
OutlookDiscovery programs Aiming for 10%–20% annual revenue
growthMaintain profitability, while strengthening
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 30
* Estimated numberspipeline
Shareholder Structure
15% Strategic Holders
15%41%
gGermanyUSAUK
11%
8%6%4%
SwitzerlandAustriaOther/Unidentified
3-for-1 stock split took place on Dec. 23, 2008
Sh I d t M h 31 2009 22 492 287Shares Issued at March 31, 2009 22,492,287Novartis ~ 7 %AstraZeneca ~ 5 %
Frankfurt Stock Exchange
ISIN: DE0006632003
SE Code: MOR
Bl b MOR GR
Management & Supervisory Board ~ 2.5 %Massachusetts Mutual Life Insurance 3.15 %
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 31
Bloomberg: MOR GRFree float 88 %
Goals 2009
• Revenues of €80 million – €85 millionCorporate • Operating profit of €8 million – €11 million Corporate
• 2 – 4 INDs• 20 new program starts
Partnered Discoveryy
• MOR103: Phase 1 data & start of phase 2 RA trialProprietary R&D p• Up to 5 new programs in cancer & inflammationProprietary R&D
• Revenues of approx. €20 million• Profit margin at least on 2008 levelAbD
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 32
Future Value Creation
Own Compounds on Market
Supporting Factors:
First HuCAL-based Drugs on Market
Financial strength makes MorphoSys independent from capital markets and
Out-licensing of Own Compounds
from capital markets and financial crisisSteady 10-20 % revenue
th
I t i O
Phase II / III Compounds
growthUse free cash flow to fund proprietary development
Invest in Own Compounds
Transformational D l ith N ti
Pipeline is increasingly the Company’s value driver
Deal with Novartis
MorphoSys Today
© MorphoSys AG© MorphoSys AG Seite 33MorphoSys AG – Company Update – April 2009
Appendix
Novartis Deal: Financial Details
Landmark deal, comprising€400m committed funding (see below)
Revenue to MorphoSys
€400m committed funding (see below)>€250m in milestones (probability-weighted assessment)Does not include royaltiesNo additional equity investment beyond current 7%No additional equity investment, beyond current 7%
Committed Approx. €400m over 10 years
Approx. half (€200m) in technology license fees plus internalization fee for Funding HuCAL, comprising contingent double digit success payment
Approx. half (€200m) in research funding for team at MorphoSys
10 years with Novartis having options to:Term
10 years, with Novartis having options to:Extend to 12 yearsTerminate after 7 years if certain technology goals are not met
Milestones & Royalties On all programs
C d l Sh d & fi ( lidi l ) d l d
© MorphoSys AG© MorphoSys AG
Co-development Shared costs & profits (sliding scale) on co-developed programs
Page 35MorphoSys AG – Company Update – April 2009
Management Boardg
Dr. Simon E. Moroney, CEODr. Moroney is one of MorphoSys’s co-founders. He studied chemistry in his native New Zealand, and was a Commonwealth Scholar to the University of Oxford, where he completed a D. Phil. in 1984. Subsequently he was an Commonwealth Scholar to the University of Oxford, where he completed a D. Phil. in 1984. Subsequently he was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc. Dr. Moroney has held positions at the University of Cambridge, UK, the University of British Columbia, Canada, and the ETH in Zurich, Switzerland. In 2002 he was awarded the German Cross of the Order of Merit by German President Johannes Rau.
Mr Dave Lemus CFOMr. Dave Lemus. CFOMr. Lemus joined the Company in 1998, and took MorphoSys public in 1999. Mr. Lemus joined MorphoSys from Roche, where he worked from 1993-1998, and last served as Controller and Operations Manager of 90 pharma-ceutical markets. Before this time, he served as Group Treasurer of Lindt & Sprüngli in Zurich, Switzerland, and prior to this, worked in treasury management for Electrolux AB in various countries. Mr. Lemus holds a B.S. degree from the University of Maryland, a M.S. degree from the MIT, and is a Certified Public Accountant (CPA) in the USA.
Dr. Arndt Schottelius, CDODr. Schottelius joined MorphoSys from Genentech Inc., San Francisco, where he served as Medical Director, Immu-nology Development. Prior to his position at Genentech, Dr. Schottelius held science and management positions in
D M li S ll CSO
gy p p , g pimmunology research at Berlex Biosciences, USA, and Schering , Germany. After medical studies in Germany, UK and Switzerland Dr. Schottelius received his PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany. Subsequently he practiced medicine as a resident physician at the Charité University Hospital, Berlin.
Dr. Marlies Sproll, CSODr. Marlies Sproll joined MorphoSys in October 2000 as R&D department head. In November 2005, Dr. Sproll was promoted to CSO. Before joining MorphoSys, Dr. Sproll worked for seven years at the Vienna research facility of Boehringer Ingelheim. From 1988 to 1993, Dr. Sproll was lab leader at Merck KGaA in Darmstadt, Germany, where she was involved in the preclinical development of therapeutic antibodies. Dr. Sproll has a Ph.D. from the Max
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 36
she was involved in the preclinical development of therapeutic antibodies. Dr. Sproll has a Ph.D. from the Max Planck Institute in Tübingen, Germany, and was awarded a Doctor of Natural Science by the University of Stuttgart.
Supervisory Boardp y
Dr. Gerald MöllerChairman
Prof. Dr. Jürgen DrewsVice Chairman
Managing Director of HBM BioVentures,Former President Boehringer-Mannheim
Former Director Global Research, F.Hoffmann-La Roche
Mannheim
Dr. Daniel CamusCFO, Electricité de France,
Dr. Walter A. BlättlerFormer Executive Vice President, C O, ect c té de a ce,
Former CFO, Aventis,
Science and Technology, ImmunoGen
Dr. Metin ColpanS i Di t QIAGEN
Dr. Geoffrey VernonCh i Zi H ldi Li it dSupervisory Director, QIAGEN
Former CEO and Founder, QIAGENChairman, Ziggus Holding LimitedFormer Executive Director Rothschild Asset Management
© MorphoSys AG© MorphoSys AG Page 37MorphoSys AG – Company Update – April 2009
Corporate Calendar 2009p
April 28, 2009 Q1 2009 ResultsApril 28 2009 LBBW German Mid & Small CapApril 28, 2009 LBBW German Mid & Small Cap
Conference, London, UKMay 13, 2009 AGM, MunichMay 18 - 19, 2009 Deutsche Bank's
34th Annual Health Care ConferenceBoston, USA
May 23-24, 2009 German & Austrian Corporate ConferenceFrankfurt, Germany
June 17-18,2009 Jefferies 3rd Annual Healthcare ConferenceJune 17 18,2009 Jefferies 3rd Annual Healthcare ConferenceNew York, USA
July 29, 2009 Q2 2009 Results
© MorphoSys AG© MorphoSys AGMorphoSys AG – Company Update – April 2009 Page 38
Covering Analystsg y
Institution Contact
B b B k M Al d R hBerenberg Bank Ms. Alexandra Roche
Commerzbank Mr. Daniel Wendorff
Credit Suisse Dr Yasir Al-WakeelCredit Suisse Dr. Yasir Al-Wakeel
Deutsche Bank Mr. Holger Blum
DZ Bank Dr. Elmar Kraus
Equinet Institutional Services Dr. Martin Possienke
Landesbank Baden-Württemberg Dr. Hanns Frohnmeyer
MIDAS Research Mr. Thomas Schiessle
Nomura Code Dr. Gary Waanders
Sal. Oppenheim Dr. Christian Peter
SG Securities Mr. Rudolphe Besserve
W tLB AG D C li Th
© MorphoSys AG© MorphoSys AG
WestLB AG Dr. Cornelia Thomas
MorphoSys AG – Company Update – April 2009 Page 39
Thank You.
www.morphosys.com
Dr. Claudia Gutjahr-LöserHead of Corporate Communications & IR
Phone +49 (0)89 / 899 27-122
Dave LemusChief Financial Officer
Phone +49 (0)89 / 899 27-439 ( )Fax +49 (0)89 / 899 27-5122Email [email protected]
( )Fax +49 (0)89 / 899 27-5439Email [email protected]
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG